

CASE STUDY


How we helped rescue
the recruitment in an

OVARIAN CANCER STUDY

Background

Pivotal, randomized, open-label
Medical Device study, for the
treatment of recurrent Ovarian
Cancer.





Challenge

- Study conducted during COVID-19 pandemic.
- The US and Canada did not recruit the planned number of patients.



Engagement

Optimapharm requested to take over this study in Europe for the following services:

- Project Management
- Feasibility
- Clinical Monitoring Services
- Ethics Committee submissions, Regulatory services
- Safety reporting
- TMF
- CTMS



Optimapharm solution

1. Selection of reliable sites, well prepared within limitations caused by the COVID-19 pandemic
2. Started the recruitment right after site activation
3. Selection of experienced CRAs
4. Involved more CRAs to deal with high recruitment and SDV backlog generated

A pregnant woman's belly is the background of the slide. A teal awareness ribbon is tied around the waist. A white text box with a blue border is overlaid on the right side of the image. A blue dotted line is on the left side of the text box. A large blue checkmark with a circular arrow is in the bottom right corner.

Outcomes

Recruitment over-achieved by 117%

- 379 patients enrolled
- Last patient out achieved in May 2023



We Deliver on Your Promises!

Explore our expertise!

[RESOURCES](#)

www.optimapharm.eu